Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Roctavian
Roctavian
BioMarin Narrows Roctavian Efforts to U.S., Germany, Italy as Sales Stagnate
BioSpace
Tue, 08/6/24 - 11:23 am
Biomarin
Roctavian
hemophilia A
Germany
Italy
BioMarin preaches patience amid slow sales for hemophilia gene therapy
BioPharma Dive
Fri, 02/23/24 - 10:26 am
Biomarin
Roctavian
earnings
gene therapy
hemophilia
BioMarin secures hemophilia gene therapy coverage in Germany
BioPharma Dive
Wed, 11/29/23 - 11:35 pm
Biomarin
Roctavian
gene therapy
Germany
hemophilia
BioMarin's share prices fluctuate following Phase 3 clinical trial results
Yahoo/Investing.com
Mon, 09/18/23 - 07:54 pm
Biomarin
Roctavian
clinical trials
With Roctavian as a launching pad, BioMarin looks to up pace of new drug filings
Fierce Biotech
Tue, 09/12/23 - 07:17 pm
Biomarin
Roctavian
hemophilia A
Voxzogo
achrondoplasia
drug development
gene therapy
Voxzogo saves the day for Biomarin
EP Vantage
Tue, 08/1/23 - 10:05 am
Biomarin
hemophilia A
gene therapy
Roctavian
Voxzogo
BioMarin's hemophilia gene therapy Roctavian lands FDA nod with 'glimmers' of enthusiasm among doctors
Fierce Pharma
Thu, 06/29/23 - 10:56 pm
BioMarin Pharmaceuticall
Roctavian
FDA
hemophilia A
gene therapy
5 FDA decisions to watch in the first quarter
BioPharma Dive
Mon, 01/9/23 - 10:27 am
FDA
Eli Lilly
donanemab
Alzheimer's disease
Menareni
Elacestrant
breast cancer
Biomarin
Roctavian
hemophilia A
Acadia Pharmaceuticals
trofinetide
Rett Syndrome
Gilead Sciences
Trodelvy
BioMarin's hemophilia gene therapy faces further delays over fresh FDA requests
Fierce Biotech
Tue, 11/8/22 - 10:46 am
Biomarin
gene therapy
FDA
hemophilia
Roctavian
Gene therapy is saving lives, but key challenges to realize its full potential
MedCity News
Thu, 10/20/22 - 10:30 am
gene therapy
Novartis
Zolgensma
Roctavian
Zynteglo
Skysona
BioMarin gets FDA decision date for hemophilia gene therapy, but questions on review remain
BioPharma Dive
Thu, 10/13/22 - 11:52 pm
Biomarin
FDA
hemophilia A
gene therapy
Roctavian
BioMarin nets conditional approval for valrox in Europe, marking the first hemophilia gene therapy
Endpoints
Thu, 08/25/22 - 10:59 am
Biomarin
hemophilia A
valrox
Europe
gene therapy
Roctavian
BioMarin's hemophilia gene therapy Roctavian wins conditional EU backing amid FDA delay
Fierce Pharma
Mon, 06/27/22 - 10:05 am
Biomarin
Roctavian
EMA
FDA
hemophilia A
valoctocogene roxaparvovec
BioMarin tries to get hemophilia gene therapy back on track with positive data
BioPharma Dive
Mon, 01/11/21 - 10:40 am
Biomarin
hemophilia A
gene therapy
clinical trials
Roctavian